Duerr Shares Rise After Takeover of BBS Automation
By David Sachs
Duerr shares rose Tuesday after the company acquired Germany-based BBS Automation Group from a consortium led by Swedish private-equity firm EQT for between 440 million and 480 million euros ($473.4 million-$516.4 million) including debt.
At 0743 GMT, shares in the German plant engineering company were up 3.4% to EUR29.54.
Duerr said it bought the automated-machinery company as part of its strategy to expand its automated technology business.
Duerr expects the takeover, which includes acquiring all of the shares in BBS's holding company, EQT-owned Rome HoldCo GmbH, to more-than double its automation revenue in 2024 to EUR500 million.
BBS founder Josef Wildbruger will stay on as manager, Duerr said.
Completion and consolidation are expected for the end of the third or beginning of the fourth quarter of 2023, Duerr said.
Baader Helvea analyst Peter Rothenaicher said in a research note that BBS seems to be a good fit for Duerr and represents a strong expansion of its automation business, one of the company's key strategic targets.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
June 13, 2023 04:14 ET (08:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?